GRFS vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jul 19, 2026
GRFS
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GRFS | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 8.3333 | 21.5517 | GRFS |
| PEG Ratio | 0.229 | 19.4203 | GRFS |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -4.8% | 1.5% | GSK |
| Earnings Growth | 43.5% | 8.4% | GRFS |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 60.4/100 | 58.9/100 | GRFS |
| Profit Margin | 5.6% | 17.8% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | BUY | HOLD | GRFS |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GRFS
NeutralMixed signals - no dominant trend phase, RSI 57
GSK
DistributionPrice near a flattening SMA50 (slope 0.2%) with fading momentum, RSI 49
Fundamentals Snapshot
| Metric | GRFS | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 5.5 | 10.1 |
| Trailing P/E | 10.8 | 17.0 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.1% |
| Gross Margin | 0.4% | 0.7% |
| Operating Margin | 0.2% | 0.3% |
| EPS | 0.76 | 3.06 |
| Dividend Yield | 0.03% | 0.03% |